We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00853047
Recruitment Status : Completed
First Posted : February 27, 2009
Results First Posted : December 26, 2018
Last Update Posted : December 26, 2018
Sponsor:
Information provided by (Responsible Party):
Lexicon Pharmaceuticals

Brief Summary:
The purpose of this study is to evaluate the safety and tolerability of telotristat etiprate (LX1606) versus a placebo control in participants with symptomatic carcinoid syndrome not managed by stable-dose long-acting octreotide therapy. Following determination of the maximally tolerated or effective dose, cohort expansion will occur to confirm effect on symptoms and safety profile.

Condition or disease Intervention/treatment Phase
Carcinoid Syndrome Drug: Telotristat etiprate Drug: Octreotide LAR Depot Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 23 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Ascending, Multidose Study To Determine Safety and Tolerability of Orally Administered LX1606 in Subjects With Symptomatic Carcinoid Syndrome Refractory to Stable-Dose Octreotide Long-Acting Release Depot Therapy
Study Start Date : March 2009
Actual Primary Completion Date : June 2014
Actual Study Completion Date : June 2014


Arm Intervention/treatment
Experimental: Telotristat Etiprate 150 mg Core Phase
Telotristat etiprate capsules,150 mg orally 3 times daily for 28 days in the double-blind treatment period (core phase) in combination with stable-dose octreotide long-acting release (LAR) depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to enter the optional open-label extension period.
Drug: Telotristat etiprate
Telotristat etiprate capsules; orally 3 times daily.
Other Name: LX1606

Drug: Octreotide LAR Depot
A stable-dose octreotide LAR depot therapy; administered subcutaneously once per month.

Experimental: Telotristat Etiprate 250 mg Core Phase
Telotristat etiprate capsules, 250 mg orally 3 times daily for 28 days in the double-blind treatment period in combination with stable-dose octreotide LAR depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to enter the optional open-label extension period.
Drug: Telotristat etiprate
Telotristat etiprate capsules; orally 3 times daily.
Other Name: LX1606

Drug: Octreotide LAR Depot
A stable-dose octreotide LAR depot therapy; administered subcutaneously once per month.

Experimental: Telotristat Etiprate 350 mg Core Phase
Telotristat etiprate capsules, 350 mg orally 3 times daily for 28 days in the double-blind treatment period in combination with stable-dose octreotide LAR depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to enter the optional open-label extension period.
Drug: Telotristat etiprate
Telotristat etiprate capsules; orally 3 times daily.
Other Name: LX1606

Drug: Octreotide LAR Depot
A stable-dose octreotide LAR depot therapy; administered subcutaneously once per month.

Experimental: Telotristat Etiprate 500 mg Core Phase
Telotristat etiprate capsules, 500 mg orally 3 times daily for 28 days in the double-blind treatment period in combination with a stable-dose octreotide LAR depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to enter the optional open-label extension period.
Drug: Telotristat etiprate
Telotristat etiprate capsules; orally 3 times daily.
Other Name: LX1606

Drug: Octreotide LAR Depot
A stable-dose octreotide LAR depot therapy; administered subcutaneously once per month.

Experimental: Placebo Core Phase
Placebo-matching telotristat etiprate capsules, orally 3 times daily for 28 days in the double-blind treatment period in combination with stable-dose octreotide LAR depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to receive telotristat etiprate in the optional open-label extension period.
Drug: Octreotide LAR Depot
A stable-dose octreotide LAR depot therapy; administered subcutaneously once per month.

Drug: Placebo
Placebo-matching telotristat etiprate capsules; orally 3 times daily.

Experimental: Telotristat Etiprate Open-Label Extension Phase
Telotristat etiprate at assigned dose level for 8 weeks in combination with stable-dose octreotide LAR depot therapy given once per month in the open-label extension period. Upon completion of the 8-week period, participants could enter an additional extension period of 172 weeks, receiving telotristat etiprate at the assigned dose or maximum tolerated dose (500 mg 3 times daily).
Drug: Telotristat etiprate
Telotristat etiprate capsules; orally 3 times daily.
Other Name: LX1606

Drug: Octreotide LAR Depot
A stable-dose octreotide LAR depot therapy; administered subcutaneously once per month.




Primary Outcome Measures :
  1. Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Drug-related TEAE in the Core Phase [ Time Frame: Up to 4 Weeks Core Phase ]
    An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. A TEAE was an AE reported after the first dose of randomized treatment on Day 1.

  2. Number of Participants With Any TEAE in the Open-Label Extension Phase [ Time Frame: Up to 180 weeks in the open-label extension phase ]
    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A TEAE was an AE reported after receiving treatment.


Secondary Outcome Measures :
  1. Change From Baseline in Mean Number of Bowel Movements (BMs) Per Day [ Time Frame: Baseline to Week 4 ]
    Participants recorded the number of BMs per day in a daily diary. The total number of BMs per day were averaged over the 4-week period. A negative change from Baseline indicates improvement.

  2. Change From Baseline in Weekly Mean Stool Form [ Time Frame: Baseline to Week 4 ]
    Participants recorded stool form in a daily diary using a 6-point scale (0-none,1-hard, 2-firm, 3-soft, 4-loose, 5-watery). A negative change from Baseline indicates improvement.

  3. Change From Baseline in Percentage of Days Per Week Experiencing a Sensation of Urgency to Defecate [ Time Frame: Baseline to Week 4 ]
    Participants recorded the sensation of urgency to defecate (Yes or No) in a daily diary. A negative change from Baseline indicates improvement.

  4. Change From Baseline in Number of Cutaneous Flushing Episodes [ Time Frame: Baseline to Week 4 ]
    Participants recorded the number of daily flushing episodes per day in a daily diary. The total number of flushing episodes per day were averaged over the 4-week period. A negative change from Baseline indicates improvement.

  5. Change From Baseline in Severity of Abdominal Pain or Discomfort [ Time Frame: Baseline to Week 4 ]
    Participants recorded the severity of abdominal pain or discomfort in a daily diary assessed using a 4-point scale (0-none, 1-mild, 2-moderate, 3-severe). A negative change from Baseline indicates improvement.

  6. Change From Baseline in Urinary 5-hydroxyindoleacetic Acid (u5-HIAA) [ Time Frame: Baseline to Week 4 ]
    u5-HIAA is a standard test used in clinical practice to assess the neuroendocrine tumor (NET) activity and is collected as a 24-hour urine specimen. A negative change from Baseline indicates improvement.

  7. Change From Baseline in Chromogranin A [ Time Frame: Baseline to Week 4 ]
    Blood samples were collected for assessment of Chromogranin A level. A negative change from Baseline indicates improvement.

  8. Number of Participants Reporting Improvement in the Subjective Global Assessment of Symptoms Associated With Carcinoid Syndrome [ Time Frame: Week 4 ]
    Participants were asked to answer the following question: "In the past 7 days, have you had adequate relief of your carcinoid syndrome bowel complaints such as diarrhea, urgent need to have a bowel movement, abdominal pain, or discomfort?". The number of participants who answered Yes are reported.

  9. Change From Baseline in Frequency of Rescue for Short-acting Octreotide Use/Day [ Time Frame: Baseline to Week 4 ]
    Participants recorded details (location and frequency of injection) of subcutaneous injections of rescue, short-acting octreotide, if taken, in the daily diary. A negative change from Baseline indicates improvement.

  10. Time to First Rescue, Short-acting Octreotide [ Time Frame: Baseline to Week 4 ]
    Time to the first subcutaneous injections of rescue, short-acting octreotide was determined from the participant's daily diary.

  11. Number of Participants Experiencing Complete Response at Week 4 [ Time Frame: Baseline to Week 4 ]
    Complete Response to treatment was defined as one of the following: 1. Less than 4 bowel movements per day; or 2. A decrease in daily bowel movements that is ≥ 50% from baseline; or 3. A positive response to the global assessment question ("In the past 7 days, have you had adequate relief of your carcinoid syndrome bowel complaints such as diarrhea, urgent need to have a bowel movement, abdominal pain or discomfort?") for each of the last 2 weeks of the Treatment Period.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males and females, aged 18 and older
  • Biopsy-proven metastatic carcinoid tumor of the gastrointestinal (GI) tract with disease extent confirmed by computed tomography (CT), magnetic resonance imaging (MRI), or radionuclide imaging
  • Symptoms not managed by stable-dose long-acting octreotide therapy (≥4 bowel movements per day)
  • Ability to provide written informed consent

Exclusion Criteria:

  • ≥12 high volume, watery bowel movements per day associated with a clinical syndrome of volume contraction, dehydration, or hypotension compatible with a "pancreatic cholera"-type clinical syndrome
  • Sponsor-unacceptable clinical laboratory values for hematology and liver function tests at screening
  • Karnofsky status ≤70% - unable to care for self
  • Surgery within 60 days prior to screening
  • A history of short bowel syndrome
  • Life expectancy <12 months
  • History of substance or alcohol abuse within 2 years prior to screening
  • Previous exposure to a tryptophan hydroxylase (TPH) inhibitor
  • Administration of any investigational drug within 30 days of screening or any therapeutic protein or antibody within 90 days of screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00853047


Locations
Layout table for location information
United States, Arkansas
Hematology Oncology Services of Arkansas
Little Rock, Arkansas, United States, 72205
United States, California
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States, 94115
United States, Indiana
St. Francis Medical Group Oncology and Hematology Specialists
Indianapolis, Indiana, United States, 46237
United States, Iowa
University of Iowa
Iowa City, Iowa, United States, 52242
United States, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115
United States, Nebraska
Nebraska Methodist Hospital
Omaha, Nebraska, United States, 68114
United States, Texas
UT M.D. Anderson Cancer Center
Houston, Texas, United States, 77030
Texas Oncology - McAllen
McAllen, Texas, United States, 78503
Texas Oncology - Weslaco
Weslaco, Texas, United States, 78596
Sponsors and Collaborators
Lexicon Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Pablo Lapuerta, MD Lexicon Pharmaceuticals, Inc.
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Lexicon Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00853047    
Other Study ID Numbers: LX1606.1-202-CS
LX1606.202 ( Other Identifier: Lexicon Pharmaceuticals, Inc. )
First Posted: February 27, 2009    Key Record Dates
Results First Posted: December 26, 2018
Last Update Posted: December 26, 2018
Last Verified: October 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoid Tumor
Malignant Carcinoid Syndrome
Syndrome
Serotonin Syndrome
Disease
Pathologic Processes
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Drug-Related Side Effects and Adverse Reactions
Chemically-Induced Disorders
Octreotide
Gastrointestinal Agents
Antineoplastic Agents, Hormonal
Antineoplastic Agents